Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs

Financing to support the development of Orbis’ pipeline of next-generation macrocycles, nCycles, with an initial focus on validated blockbuster biologic targets Orbis’ nGen platform systematically explores oral macrocycle design with automated chemistry and machine learning Novo Holdings…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.